한글목차

거대세포바이러스(CMV) 치료 세계 시장은 2030년까지 6억 2,690만 달러에 달할 전망

2023년에 4억 6,050만 달러로 추정된 거대세포바이러스(CMV) 치료 세계 시장은 2023-2030년 분석 기간에 CAGR 4.5%로 성장하여 2030년에는 6억 2,690만 달러에 달할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 암시클로비르 의약품은 CAGR 4.9%로 성장을 지속하고, 분석 기간 종료 시에는 2억 2,790만 달러에 달할 것으로 예측됩니다. Valgan Cyclovir 의약품 부문의 성장률은 분석 기간 동안 CAGR 6.1%로 추정됩니다.

미국 시장은 1억 2,550만 달러로 추정, 중국은 CAGR 7.5%로 성장 예측

미국의 거대세포바이러스(CMV) 치료 시장은 2023년 1억 2,550만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 7.5%로 성장해 2030년에는 1억 2,830만 달러 규모에 이를 것으로 예측되고 있습니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.7%와 4.7%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 2.7%로 성장할 것으로 예측됩니다.

세계의 거대세포바이러스(CMV) 치료 시장 - 주요 촉진요인 및 동향 요약

거대세포바이러스(CMV)는 모든 연령대의 사람들을 감염시킬 수있는 일반적인 바이러스이며 면역 결핍증, 신생아 및 임신 한 여성에게 심각한 건강 피해를 초래합니다. CMV 치료에는 바이러스를 관리하고 제어하고 신체에 미치는 영향을 줄이기 위해 고안된 항바이러스제물이 사용됩니다. 이러한 치료는 유아의 장기 장애, 청력 상실, 발달 장애와 같은 심각한 합병증을 예방하는 데 매우 중요합니다. CMV 치료에 사용되는 일반적인 항바이러스제는 간시클로비르, 발간시클로비르, 포스카르넷, 시드포비르 등을 포함하며, 각각 환자별 요인에 따라 투여 방법 및 적합성이 다릅니다.

CMV 치료의 상황은 의학 연구의 진보와 바이러스에 대한 더 깊은 이해의 영향을 받아, 해마다 크게 변화하고 있습니다. 분자진단 기술의 발전으로 조기 발견과 진단이 향상되었습니다. 이로써 CMV 감염을 효과적으로 관리하는데 있어서 매우 중요한 시기 적절한 개입이 가능해졌습니다. 또한 연구개발은 효능과 안전성이 뛰어난 새로운 항바이러스제와 치료요법을 개발하고 있습니다. 이러한 진보에도 불구하고, 특히 약물 내성과 일부 환자에서 장기 투약의 필요성 등 과제도 남아 있습니다. 현재 진행 중인 연구는 이러한 문제를 해결하기 위한 것이며, 여러 가지 새로운 치료법과 백신이 현재 다양한 개발 단계에 있습니다.

CMV 치료 시장의 성장은 기술 혁신, CMV 감염의 유병률 증가, 헬스케어 인프라 확대 등 여러 요인에 의해 야기됩니다. 진단 도구의 기술적 진보는 CMV의 조기적이고 정확한 검출을 용이하게 하여 시기 적절한 치료와 환자의 예후 개선으로 이어졌습니다. CMV와 그 잠재적 합병증에 대한 의식 증가는 특히 장기 이식을 받은 환자와 신생아와 같은 고위험 집단에서 스크리닝 증가로 이어졌습니다. 게다가 새로운 항바이러스제물과 치료 전략의 개발은 치료 옵션을 넓히고, 효능을 향상시키고, 부작용을 감소시킵니다. 예방 의료 및 정기 검진의 중시 등 소비자 행동의 동향도 시장의 성장에 기여하고 있습니다. 게다가 신흥 시장에서의 헬스케어 서비스의 확대나 세계의 의료 지출 증가는 CMV 치료 시장의 추가 성장을 가속할 것으로 예상됩니다. 이러한 요인들이 결합되어 CMV 치료 시장의 역동적이고 유망한 미래가 약속되고 있습니다.

조사 대상 기업 예(주목 42사)

• Bristol-Myers Squibb Company
• CHEPLAPHARM Arzneimittel GmbH
• Eurofins Viracor, LLC
• F. Hoffmann-La Roche AG
• Fresenius Kabi USA
• Genentech, Inc.
• Gilead Sciences, Inc.
• Kamada Ltd.
• Merck & Co., Inc.
• Pfizer, Inc.
• Roche Diagnostics Corporation
• Takeda Pharmaceutical Company Limited
• Teva Canada Limited
• The Native Antigen Company
• Thermo Fisher Scientific, Inc.;

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트(UAE)
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Cytomegalovirus (CMV) Treatment Market to Reach US$626.9 Million by 2030

The global market for Cytomegalovirus (CMV) Treatment estimated at US$460.5 Million in the year 2023, is expected to reach US$626.9 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Ganciclovir Drugs, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$227.9 Million by the end of the analysis period. Growth in the Valganciclovir Drugs segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$125.5 Million While China is Forecast to Grow at 7.5% CAGR

The Cytomegalovirus (CMV) Treatment market in the U.S. is estimated at US$125.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$128.3 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Cytomegalovirus (CMV) Treatment Market - Key Drivers and Trends Summarized

Cytomegalovirus (CMV) is a common virus that can infect people of all ages, with significant health implications for immunocompromised individuals, newborns, and pregnant women. CMV treatment involves antiviral medications designed to manage and control the virus, reducing its impact on the body. These treatments are critical for preventing severe complications, such as organ damage, hearing loss, and developmental issues in infants. Common antiviral drugs used in CMV treatment include ganciclovir, valganciclovir, foscarnet, and cidofovir, each varying in administration methods and suitability based on patient-specific factors.

The CMV treatment landscape has evolved significantly over the years, influenced by advancements in medical research and a better understanding of the virus. Early detection and diagnosis have improved, thanks to advancements in molecular diagnostic techniques. This has allowed for timely intervention, which is crucial in managing CMV infections effectively. Research has also led to the development of new antiviral agents and treatment regimens that offer better efficacy and safety profiles. Despite these advancements, challenges remain, particularly regarding drug resistance and the need for long-term medication in some patients. The ongoing research aims to address these issues, with several new therapies and vaccines currently in various stages of development.

The growth in the CMV treatment market is driven by several factors, including technological innovations, increasing prevalence of CMV infections, and expanding healthcare infrastructure. Technological advancements in diagnostic tools have facilitated early and accurate detection of CMV, leading to timely treatment and better patient outcomes. The rising awareness about CMV and its potential complications has led to increased screening, particularly among high-risk populations such as organ transplant recipients and newborns. Additionally, the development of novel antiviral drugs and therapeutic strategies has expanded treatment options, improving efficacy and reducing side effects. Consumer behavior trends, such as the growing emphasis on preventive healthcare and regular medical check-ups, have also contributed to market growth. Furthermore, the expansion of healthcare services in emerging markets and increased healthcare spending globally are expected to drive further growth in the CMV treatment market. These factors collectively ensure a dynamic and promising future for the CMV treatment landscape.

Select Competitors (Total 42 Featured) -

• Bristol-Myers Squibb Company
• CHEPLAPHARM Arzneimittel GmbH
• Eurofins Viracor, LLC
• F. Hoffmann-La Roche AG
• Fresenius Kabi USA
• Genentech, Inc.
• Gilead Sciences, Inc.
• Kamada Ltd.
• Merck & Co., Inc.
• Pfizer, Inc.
• Roche Diagnostics Corporation
• Takeda Pharmaceutical Company Limited
• Teva Canada Limited
• The Native Antigen Company
• Thermo Fisher Scientific, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Cytomegalovirus (CMV) Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Cytomegalovirus Infections Drives Demand for CMV Treatment
  • Advancements in Antiviral Therapies Propel Growth in CMV Treatment Market
  • Increasing Awareness of CMV and Its Complications Expands Addressable Market Opportunity
  • Innovations in Vaccine Development Strengthen Business Case for CMV Prevention
  • Expansion of Neonatal and Pediatric Care Facilities Spurs Market Growth
  • Growing Focus on Immunocompromised Patients Drives Adoption of CMV Therapies
  • Development of Combination Therapies Generates Market Interest
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cytomegalovirus (CMV) Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cytomegalovirus (CMV) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Ganciclovir Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Ganciclovir Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Ganciclovir Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Valganciclovir Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Valganciclovir Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Valganciclovir Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Cidofovir Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Cidofovir Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Cidofovir Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Foscarnet Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Foscarnet Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Foscarnet Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Organ Transplantation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Organ Transplantation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Organ Transplantation Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Congenital CMV Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Congenital CMV Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Congenital CMV Infection Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Stem Cell Transplantation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Stem Cell Transplantation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Stem Cell Transplantation Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• JAPAN
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• CHINA
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: China 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: China 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: China 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• EUROPE
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Cytomegalovirus (CMV) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• FRANCE
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: France 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: France 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: France 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• GERMANY
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Cytomegalovirus (CMV) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• INDIA
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 175: India 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 178: India 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 181: India 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Cytomegalovirus (CMV) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Cytomegalovirus (CMV) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• AFRICA
  • Cytomegalovirus (CMV) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Cytomegalovirus (CMV) Treatment by Drug Class - Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Drug Class - Percentage Breakdown of Value Sales for Ganciclovir Drugs, Valganciclovir Drugs, Cidofovir Drugs, Foscarnet Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Cytomegalovirus (CMV) Treatment by Application - Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Application - Percentage Breakdown of Value Sales for Organ Transplantation Application, Congenital CMV Infection Application, Other Applications and Stem Cell Transplantation Application for the Years 2014, 2024 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Cytomegalovirus (CMV) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Cytomegalovirus (CMV) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION